Skip to main content

CJC-1295 (no DAC) vs Ipamorelin

Both CJC-1295 (no DAC) and Ipamorelin are used for growth-hormone and anti-aging. Here's how their evidence, dosing, and regulatory status actually compare.

CJC-1295 (no DAC)

Evidence B

Modified Growth Hormone Releasing Factor 1-29

A growth hormone releasing hormone (GHRH) analog most commonly stacked with Ipamorelin to stimulate natural GH pulsatile release without disrupting the hypothalamic axis.

View full CJC-1295 (no DAC) profile →

Ipamorelin

Evidence B

Ipamorelin Acetate

A selective growth hormone secretagogue that triggers GH release from the pituitary without significantly raising cortisol or prolactin. The safest GH peptide with the fewest side effects.

View full Ipamorelin profile →

Side-by-Side

AttributeCJC-1295 (no DAC)Ipamorelin
Evidence GradeBB
FDA StatusNot FDA-approved — Category 1 (compounding allowed)Not FDA-approved — Category 1 (compounding allowed)
Typical Dose100–300 mcg before bed (subcutaneous)100–300 mcg before bed (subcutaneous)
Clinics Indexed156195
Categoriesgrowth-hormone, anti-aging, recoverygrowth-hormone, anti-aging

Key reported benefits — CJC-1295 (no DAC)

  • Growth hormone release
  • Fat loss
  • Improved sleep
  • Muscle recovery

Key reported benefits — Ipamorelin

  • Clean GH release
  • Improved sleep quality
  • Fat reduction
  • Joint health

Educational use only

This comparison is for educational purposes and not medical advice. Peptide selection should be made with a licensed medical professional based on your individual goals, health history, and current evidence quality.

← Back to all comparisons